An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants, \>/= 18 years of age
Granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to Chapel Hill Consensus Conference Definitions for MPA and American College of Rheumatology (ACR) Criteria for the Classification of GPA
Disease severity requiring rituximab treatment per the investigator's assessment
You may not be if
Prior use of rituximab (except if received within 4 weeks of screening)
Known hypersensitivity to rituximab, to any component of the product, or to murine proteins
Pregnant or breastfeeding women
Diagnosis of Churg-Strauss syndrome
Clareo Health | An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
